These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35122060)

  • 41. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy.
    Monteran L; Erez N
    Trends Cancer; 2023 Jan; 9(1):1-2. PubMed ID: 36371342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trials and tribulations of pancreatic cancer immunotherapy.
    Principe DR; Korc M; Kamath SD; Munshi HG; Rana A
    Cancer Lett; 2021 Apr; 504():1-14. PubMed ID: 33549709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.
    Douglas JE; Liu S; Ma J; Wolff RA; Pant S; Maitra A; Tamm EP; Bhosale P; Katz MHG; Varadhachary GR; Koay EJ
    BMC Cancer; 2022 Jan; 22(1):14. PubMed ID: 34980020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
    Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
    Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
    Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
    J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
    Li S; Na R; Li X; Zhang Y; Zheng T
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites.
    Luchini C; Mafficini A; Chatterjee D; Piredda ML; Sciammarella C; Navale P; Malleo G; Mattiolo P; Marchegiani G; Pea A; Salvia R; Brosens LA; Paolino G; Mastrosimini MG; Silvestris N; Milella M; Cheng L; Adsay VN; Lawlor RT; Scarpa A
    Virchows Arch; 2022 Jun; 480(6):1261-1268. PubMed ID: 34613461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy for pancreatic cancer: A 2020 update.
    Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
    Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
    Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
    Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune signature as a potential marker for predicting response to immunotherapy in obesity-associated colorectal cancer.
    Park S; An J; Ha SY; Nam S; Kim JH
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1579-1587. PubMed ID: 35680621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
    Hecht JR; Papadopoulos KP; Falchook GS; Patel MR; Infante JR; Aljumaily R; Wong DJ; Autio KA; Wainberg ZA; Bauer TM; Javle M; Pant S; Bendell J; Hung A; Ratti N; VanVlasselaer P; Verma R; Leveque J; Rao S; Oft M; Naing A
    Invest New Drugs; 2021 Feb; 39(1):182-192. PubMed ID: 32910338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.